Business
Quest PharmaTech Announces Results from its 2017 AGM
Quest PharmaTech Announces Results from its 2017 AGM Canada NewsWire EDMONTON, F...
About this update from Quest Pharmatech Inc.
[{"type":"text","content":"\n\n\n\nQuest PharmaTech Announces Results from its 2017 AGM\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nEDMONTON, Feb. 15, 2017\n\n\n\nTSX Venture: QPT\n\n\n\nEDMONTON, Feb. 15, 2017 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT) (\"Quest\" or the \"Company\"), a pharmaceutical company developing and commercializing products to improve the quality of life, today announced the results of its February 9, 2017 annual general meeting of shareholders. \n\nThe Company is pleased to announce the following 5 directors have been re-elected to the Company's Board of Directors:\n\nLorne Meikle, BA Ian McConnan, FCA, Eric Shi, MD, Ph.D.Shawn Lu, MBA, Mfin, CIM, CCAMadi R. Madiyalakan, Ph.D.\n\nMr. Meikle, Mr. McConnan and Dr. Shi are all independent directors.  Mr. Meikle is the Chairman of the Board.  Mr. McConnan is Chair of the Audit Committee.  Dr. Shi is Chair of the Corporate Governance Committee and Mr. Lu is Chair of the Compensation Committee.\n\n\"We wish to thank our shareholders for their continuing support,\" said Dr. Madi R. Madiyalakan, Chief Executive Officer for Quest.  With the strength and experience of our re-elected Board members, I am confident that Quest's Board of Directors will be able to help the Company execute its business strategy to add value to our shareholders.\"\n\nApproximately 74,500,000 shares were voted for the Company's shareholder meeting representing 49.5% of the Company's shares eligible to vote.  Shareholder's voted 99% in favor of all meeting resolutions.\n\nIn addition, the Company announced the granting of 600,000 stock options to Directors and 650,000 stock options to Officers, all at an exercise price of $0.15 per common share, subject to TSX Venture Exchange approval. \n\nAbout Quest PharmaTech Inc. Quest PharmaTech is a publicly traded, Canadian based pharmaceutical company developing products to improve the quality of life. The Company through its subsidiary, OncoQuest is developing antibody based immunotherapeutic products for cancer.  In addition, the Company owns the Photodynamic T...